Cardiac Amyloidosis Clinical Trial
Official title:
Artificial Intelligence Guided Echocardiographic Screening of Rare Diseases
Despite rapidly advancing developments in targeted therapeutics and genetic sequencing, persistent limits in the accuracy and throughput of clinical phenotyping has led to a widening gap between the potential and the actual benefits realized by precision medicine. Recent advances in machine learning and image processing techniques have shown that machine learning models can identify features unrecognized by human experts and more precisely/accurately assess common measurements made in clinical practice. The investigators have developed an algorithm, termed EchoNet-LVH, to identify cardiac hypertrophy and identify patients who would benefit from additional screening for cardiac amyloidosis and will prospectively evaluate its accuracy in identifying patients whom would benefit from additional screening for cardiac amyloidosis.
Despite rapidly advancing developments in targeted therapeutics and genetic sequencing, persistent limits in the accuracy and throughput of clinical phenotyping has led to a widening gap between the potential and the actual benefits realized by precision medicine. This conundrum is exemplified by current approaches to assessing morphologic alterations of the heart. If reliably identified, certain cardiac diseases (e.g. cardiac amyloidosis and hypertrophic cardiomyopathy) could avoid misdiagnosis and receive efficient treatment initiation with specific targeted therapies. The ability to reliably distinguish between cardiac disease types of similar morphology but different etiology would also enhance specificity for linking genetic risk variants and determining mechanisms Recent advances in machine learning and image processing techniques have shown that machine learning models can identify features unrecognized by human experts and more precisely/accurately assess common measurements made in clinical practice. In echocardiography, this ability for precision measurement and detection is important in both disease screening as well as diagnosis of cardiovascular disease. Echocardiography is routinely and frequently used for diagnosis and prognostication in routine clinical care, however there is often subjectivity in interpretation and heterogeneity in application. Human attention is fatigable and has heterogenous interpretation between providers. AI guided disease screening workflows have been proposed for rare diseases such as cardiac amyloidosis and other diseases with relatively low prevalence but significant human impact with targeted therapies when detected early. This is an area particularly suitable for AI as there are multiple mimics where diseases like hypertrophic cardiomyopathy, cardiac amyloidosis, aortic stenosis, and other phenotypes might visually be similar but can be distinguished by AI algorithms. The investigators have developed an algorithm, termed EchoNet-LVH, to identify cardiac hypertrophy and identify patients who would benefit from additional screening for cardiac amyloidosis, hypertrophic cardiomyopathy and other diseases. E ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04459169 -
Cardiac Amyloidosis : Diagnostic Using Red Flag Signals
|
||
Recruiting |
NCT03029026 -
The Role of Occult Cardiac Amyloid in the Elderly With Aortic Stenosis.
|
||
Recruiting |
NCT06034405 -
Analysis of Lumbar Spine Stenosis Specimens for Identification of Transthyretin Cardiac Amyloidosis
|
||
Recruiting |
NCT04915235 -
Prevalence and Prognosis of Cardiac Amiloidosis in Turkey
|
||
Recruiting |
NCT02966522 -
Thalidomide/Dexamethasone Treatment And PET Evaluation In Organ Involvemenet of Cardiac Amyloidosis
|
Phase 2 | |
Terminated |
NCT03333551 -
Cardiac Uptake of 18F Florbetapir in Patients Undergoing Chemotherapy
|
Phase 4 | |
Recruiting |
NCT04105634 -
Molecular Imaging of the Underlying Mechanism of Cardiotoxicity in Patients With Light Chain Amyloidosis Using PET/CT
|
Early Phase 1 | |
Not yet recruiting |
NCT05593679 -
A Multi-center Cardiac PYP Scan Registry in Taiwan.
|
||
Not yet recruiting |
NCT04146415 -
Diagnosis of Cardiac Amyloidosis With 99mTc-PYP; Comparison Between Planar Imaging, SPECT/CT and Cardiac-dedicated CZT Camera
|
N/A | |
Not yet recruiting |
NCT06427304 -
Cardiac Amyloidosis pRevaleNce of in OLDer Subjects Affected by Heart Failure
|
||
Recruiting |
NCT06469372 -
Cardiac Amyloidosis Discovery Trial
|
N/A | |
Recruiting |
NCT04856267 -
Exploration of Arrhythmia Burden in Cardiac Amyloidosis Using Implantable Loop Recorders
|
||
Completed |
NCT03119558 -
PET/MRI Evaluation of Cardiac Amyloid
|
Early Phase 1 | |
Recruiting |
NCT02798705 -
Physiologic Assessment of Microvascular Function in Patients With Cardiac Amyloidosis
|
||
Not yet recruiting |
NCT04387344 -
Morpho-functional Cardiac Modifications in Treated Mutated Transthyretin Cardiac Amyloidosis
|
||
Recruiting |
NCT06129656 -
Cardiac Amyloidosis Registry of University Hospital Leipzig
|
||
Terminated |
NCT01683825 -
Imaging Cardiac Amyloidosis: A Pilot Study Using F-18 Florbetapir Positron Emission Tomography
|
Phase 4 | |
Withdrawn |
NCT04363294 -
Targeted Testing for ATTR Among Aortic Stenosis Patients-Pilot
|
N/A | |
Not yet recruiting |
NCT04661800 -
Study of Olfactory Disorders in Patients With Cardiac Amyloidosis
|
N/A | |
Terminated |
NCT03232632 -
Assessment of Cardiac Fixation During PET Using a New Drug Within Amyloid Cardiac Injuries.
|
Early Phase 1 |